Trial Profile
Prospective observational study of SGLT2 inhibitor, ipragliflozin in patients with type 2 diabetes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Apr 2018
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- 04 Apr 2018 Status changed from active, no longer recruiting to completed.
- 27 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 03 Jun 2016 New trial record